Novocure Announces Six Clinical Presentations on Novocure’s Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology

An oral presentation will focus on how compliance and treatment duration may predict survival in newly diagnosed glioblastoma patients treated with Optune® together with temozolomide In total, 54 abstracts on Tumor Treating Fields, including two oral presentations, will be presented The volume of Tumor Treating Fields presentations marks a record number of abstracts ST. HELIER, …